| Literature DB >> 26464850 |
Dipika Bansal1, Kapil Gudala1, Hari Prasad Esam1, Ramya Nayakallu1, Raja Vikram Vyamusani1, Anil Bhansali2.
Abstract
The study was aimed at assessing the prevalence of microvascular complications and associated risk factors in newly diagnosed type 2 diabetes mellitus patients. A cross-sectional study was conducted in a public tertiary care hospital. All the recruited patients underwent extensive examination for the presence of microvascular complications like neuropathy, retinopathy, and nephropathy. Prevalence of any complication was 18.04%. Prevalence of neuropathy, retinopathy, and nephropathy was found to be 8.2%, 9.5%, and 2.8%, respectively. Triglycerides (OR, 1.01; P = 0.011) and old age (OR, 1.06; P ≤ 0.01) were significantly associated with any complication. Triglycerides were significantly associated with neuropathy (OR, 1.01; P = 0.05) and retinopathy (OR, 1.01; P = 0.02). Being male posed high risk for nephropathy (OR, 0.06; P = 0.01). These results are suggesting need of regular screening for microvascular complications.Entities:
Year: 2014 PMID: 26464850 PMCID: PMC4590918 DOI: 10.1155/2014/201423
Source DB: PubMed Journal: Int J Chronic Dis ISSN: 2314-5749
Clinical and biochemical characteristics of patients with newly diagnosed diabetes mellitus (n = 449).
| Variables | No microvascular complication ( | Any one of the three complications ( |
|
|---|---|---|---|
| Age* | 49.3 ± 10.2 | 56.0 ± 8.9 | <0.0001a |
| Duration of diabetes (years)# | 0.2 (0.1–0.4) | 0.16 (0.1–0.3) | 0.211b |
| Gender | 173 (47) | 33 (41) | 0.326c |
| Gender | 195 (53) | 48 (59) | |
| BMI (Kg/m2)* | 27.4 ± 5.2 | 27.2 ± 4.5 | 0.748a |
| Waist circumference (cm)* | 96.5 ± 13.1 | 96.9 ± 12.9 | 0.803a |
| Hypertension | 196 (53) | 35 (43) | 0.112c |
| TC (mg/dL)* | 200 ± 53 | 193 ± 58 | 0.313a |
| LDL C (mg/dL)* | 117 ± 37 | 110 ± 43 | 0.158a |
| HDL C (mg/dL)* | 42 ± 10 | 42 ± 8 | 0.724a |
| TG (mg/dL)# | 103 (37–165) | 150 (92–198) | 0.005b |
| HbA1c* | 8.2 ± 2.3 | 9.1 ± 2.5 | 0.001a |
| Serum creatinine# | 0.8 (0.7–0.9) | 0.8 (0.7–0.9) | 0.122b |
| Smoking | 48 (13) | 7 (9) | 0.364c |
| Alcohol | 69 (19) | 10 (12) | 0.226c |
| Socioeconomic status | |||
| Upper | 45 (12) | 9 (11) | 0.235c |
| Middle | 250 (68) | 49 (61) | |
| Lower | 73 (20) | 23 (28) |
*Expressed as mean ± standard deviation and #median interquartile range. aAnalyzed using independent sample test, banalyzed using Mann-Whitney test, and canalyzed using chi-square test; TC: total cholesterol, LDL-C: low density lipoprotein cholesterol, HDL-C: high density lipoprotein cholesterol, TGs: triglycerides, and HbA1c: glycated hemoglobin.
Figure 1Prevalence of microvascular complications in newly diagnosed diabetes mellitus patients (n = 449).
Risk factors for microvascular complications in patients with newly detected diabetes mellitus.
| Risk factor | Any microvascular complication | Neuropathy | NPDR | PDR | Nephropathy | |||||
|---|---|---|---|---|---|---|---|---|---|---|
| Odds ratio (95% CI) |
| Odds ratio (95% CI) |
| Odds ratio (95% CI) |
| Odds ratio (95% CI) |
| Odds ratio (95% CI) |
| |
| Age | 1.06 (1.03–1.08) | <0.01* | 1.08 (1.04–1.12) | <0.01* | 1.02 (0.99–1.06) | 0.172 | 1.00 (0.95–1.05) | 0.851 | 1.00 (0.95–1.06) | 0.816 |
| Female gender | 1.17 (0.71–1.93) | 0.518 | 1.36 (0.67–2.77) | 0.383 | 0.99 (0.45–2.21) | 0.993 | 2.85 (0.91–8.89) | 0.070 | 0.06 (0.01–0.51) | 0.01* |
| BMI | 0.99 (0.94–1.04) | 0.746 | 0.98 (0.91–1.05) | 0.621 | 0.97 (0.89–1.05) | 0.490 | 1.05 (0.96–1.15) | 0.279 | 0.99 (0.89–1.10) | 0.910 |
| SBP | 1.01 (0.98–1.02) | 0.623 | 0.98 (0.96–1.01) | 0.379 | 1.01 (0.99–1.03) | 0.224 | 1.01 (0.97–1.03) | 0.834 | 1.01 (0.98–1.04) | 0.470 |
| HbA1c | 1.24 (1.12–1.37) | 0.047* | 1.01 (0.84–1.2) | 0.897 | 1.33 (1.16–1.53) | 0.045* | 1.88 (1.13–2.34) | 0.034* | 0.92 (0.70–1.22) | 0.593 |
| Total cholesterol | 0.99 (0.98–1.01) | 0.489 | 0.98 (0.97–0.99) | 0.013 | 1.00 (0.99–1.01) | 0.254 | 1.00 (0.99–1.01) | 0.864 | 1.00 (0.99–1.01) | 0.607 |
| LDL | 0.99 (0.98–1.01) | 0.483 | 0.98 (0.97–0.99) | 0.011 | 1.00 (0.99–1.01) | 0.393 | 1.00 (0.99–1.01) | 0.486 | 1.00 (0.99–1.02) | 0.327 |
| HDL | 0.99 (0.96–1.02) | 0.681 | 0.99 (0.94–1.04) | 0.728 | 0.98 (0.93–1.02) | 0.408 | 1.01 (0.95–1.07) | 0.697 | 0.99 (0.92–1.06) | 0.882 |
| TG | 1.01 (1.00–1.02) | 0.011* | 1.01 (1.0–1.02) | 0.05* | 1.01 (1.00–1.02) | 0.02* | 0.99 (0.98–1.01) | 0.764 | 1.01 (1.00–1.02) | 0.032* |
| Serum creatinine | 0.91 (0.54–1.55) | 0.753 | 0.78 (0.27–2.27) | 0.659 | 0.26 (0.08–0.84) | 0.024 | 0.73 (0.20–2.70) | 0.643 | 1.55 (1.26–2.59) | 0.047* |
| Smoking | 0.73 (0.33–1.59) | 0.434 | 0.89 (0.32–2.46) | 0.825 | 0.89 (0.25–3.09) | 0.854 | 0.42 (0.05–3.25) | 0.408 | 1.27 (0.27–5.93) | 0.761 |
| Alcohol | 0.56 (0.27–1.15) | 0.118 | 1.02 (0.42–2.46) | 0.962 | 0.17 (0.02–1.31) | 0.091 | 0.67 (0.33–2.84) | 0.853 | 0.82 (0.18–3.80) | 0.805 |
*Statistically significant; the odds ratio for each variable or factors was adjusted for risk factors like age, HbA1c, PPG, HDL, BMI, LDL, TC, smoking, and alcohol status; TC: total cholesterol, LDL-C: low density lipoprotein cholesterol, HDL-C: high density lipoprotein cholesterol, TGs: triglycerides, HbA1c: glycated hemoglobin, NPDR: nonproliferative diabetic retinopathy, and PDR: proliferative diabetic retinopathy.
Prescribing pattern of antihyperglycemic and concurrent medication in patients with newly diagnosed diabetes mellitus (n = 449).
| Class of antidiabetic medication | Percentage prescribed |
|---|---|
| Biguanides | 333 (74) |
| Sulfonylureas | 175 (39) |
| Thiazolidinediones | 29 (6) |
| Insulin | 167 (37) |
| Antihypertensives | 176 (39) |
| Antiplatelets | 29 (6) |
| Lipid lowering | 47 (10) |
| Combination | |
| Insulin alone | 47 (11) |
| Insulin + OHA | 120 (27) |
| OHA | 359 (80) |
| OHA monotherapy | 196 (44) |
| Biguanides | 175 (39) |
| Sulfonylureas | 21 (5) |
| OHA dual therapy | 147 (33) |
| Biguanides + sulfonylureas | 133 (30) |
| Biguanides + thiazolidinediones | 8 (2) |
| Sulfonylureas + thiazolidinediones | 5 (1) |
| OHA polytherapy | 16 (4) |
| Sulfonylureas + biguanides + | 16 (4) |
OHA: oral hypoglycemic agents.